Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
(NASDAQ: LTRN) Delayed: 1.55 -0.16 (9.36%)
Previous Close $1.71    52 Week High $ 
Open $1.75    52 Week Low $ 
Day High $1.75    P/E N/A 
Day Low $1.55    EPS $ 
Volume 190,533